Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01798303 · ClinicalTrials.gov registry record · Phase 2
A Study of LY2940094 in Participants With Alcohol Dependency
A Phase 2 study of Alcoholism, sponsored by BlackThorn Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 88
- Enrollment target
- 5
- Study locations
NCT01798303 is a Phase 2 study of Alcoholism that has completed, run by BlackThorn Therapeutics. The registered enrollment target is 88 participants, below the 374-participant average among 65 other Alcoholism trials with a reported enrollment target (76% lower). The trial reports 5 study locations across 5 states.
The verdict
NCT01798303, a Phase 2 study of Alcoholism, has completed, sponsored by BlackThorn Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 88 participants
- Enrollment target
- 5
- Study locations
Study Summary
The main purpose of this study is to evaluate a once daily (QD) 40-milligram (mg) oral dose of LY2940094 in participants with an alcohol dependency to evaluate if LY2940094 will reduce alcohol drinking in these participants. The study will last for 8 weeks.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG LY2940094
Study Locations (5)
Connecticut
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - New Haven
Florida
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - North Miami
Indiana
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Indianapolis
Oregon
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Portland
South Carolina
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Charleston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 88 participants |
| Start Date | 2013-07 |
| Est. Completion | 2014-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01798303
The ClinicalTrials.gov registry entry for NCT01798303 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 88 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 374-participant average among 65 other Alcoholism trials with a reported enrollment target (76% lower). The listed sponsor is BlackThorn Therapeutics, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Alcoholism appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01798303 reports 5 study locations spanning 5 distinct geographic areas - top geographies include Connecticut, Florida, Indiana.
Frequently Asked Questions
What is clinical trial NCT01798303 about?
NCT01798303 is a clinical study titled "A Study of LY2940094 in Participants With Alcohol Dependency". The main purpose of this study is to evaluate a once daily (QD) 40-milligram (mg) oral dose of LY2940094 in participants with an alcohol dependency to evaluate if LY2940094 will reduce alcohol drinking in these participants. The study will last for 8 weeks.
What is the current status of trial NCT01798303?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 88 participants. The study started on 2013-07. Estimated completion is 2014-06.
What conditions does trial NCT01798303 study?
This clinical trial studies the following conditions: Alcoholism.
What interventions are being tested in trial NCT01798303?
The interventions under investigation include: Placebo (DRUG), LY2940094 (DRUG).
Who is sponsoring clinical trial NCT01798303?
This trial is sponsored by BlackThorn Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01798303 being conducted?
This trial has 5 study locations across Connecticut, Florida, Indiana, Oregon, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alcoholism
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Ketamine Alcohol (in Treatment-Resistant Depression)
RECRUITING · Phase 2
-
Ibudilast for Treating Alcohol Use Disorder
ACTIVE NOT RECRUITING · Phase 2
-
Gabapentin Treatment of Alcohol Dependence
COMPLETED · Phase 2
-
Treatment With Mecamylamine in Smoking and Non-smoking Alcohol Dependent Patients
COMPLETED · Phase 2
-
Combination of Disulfiram Plus Naltrexone to Treat Both Cocaine- and Alcohol-dependent Individuals - 1
COMPLETED · Phase 2
-
Drug Therapy for Alcohol Dependence in Alaska Natives (Naltrexone/Sertraline)
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.